Moreover, the influence of each cardiac complication on HSCTrelated outcomes remains unclear. Therefore, we conducted a single-center retrospective study to examine patients who developed acute pericarditis before engraftment in HSCT.
We included 464 adult patients (⩾16 years old) who underwent HSCT between 1995 and 2014 at The University of Tokyo Hospital, Japan. Of these, 284 patients were males (61.2%) and the median age was 42 years. Acute myeloid leukemia (n = 160) was the most common condition followed by acute lymphoblastic leukemia (n = 94), chronic myeloid leukemia (n = 59), lymphoma (n = 56), myelodysplastic syndrome (n = 53) and other diseases (n = 42). In total, 352 patients (75.9%) received conventional myeloablative conditioning (MAC) regimens comprising the following: (i) 120 mg/kg of cyclophosphamide (Cy)+12 Gy of TBI, (ii) 30 mg/kg of VP-16+120 mg/kg of Cy+12 Gy of TBI+6 g/m 2 of AraC, (iii) 40 mg/kg of VP-16+40 mg/kg of Cy+12 Gy of TBI and (iv) 16 mg/kg oral or 12.8 mg/kg IV busulfan+120 mg/kg Cy+0 to 4 Gy of TBI. More than half of the patients received HSCT from unrelated donors (260; 56.0%), and most received HSCT from an HLA-matched donor (331; 71.3%). Regarding stem cell source, 301 patients (64.9%) received bone marrow transplantation (BMT), 122 patients received PBSCs (26.3%), and the other patients received cord blood (8.8%).
We identified four patients (0.9%) with acute pericarditis before engraftment (Table 1) according to the following diagnostic criteria: presence of acute chest pain, presence of diffuse ST-segment elevation on electrocardiography, and absence of signs of other cardiac complications (for example, myocardial infarction, angina pectoris or myocarditis); all the patients were found to meet the above-mentioned criteria. They all received TBI as a part of conditioning regimens, and received hematopoietic stem cell from unrelated donors. No patient who received HSCT from HLA-mismatched donor experienced acute pericarditis. Pre-transplant examinations showed no cardiac abnormality in all patients. No pathogens were detected by blood cultures from all patients or by PCR testing of blood (except for case 1) for the following viruses: Epstein-Barr virus, CMV, parvovirus B19, herpes simplex (type 1 and 2), VZV, human herpesvirus (type 6, 7 and 8), adenovirus, JC virus, BK virus, echovirus and Coxsackie virus. Three of the patients recovered quickly with simple supportive care, but one patient (case 2) developed constrictive pericarditis with pericardial bleeding.
Case 2 was a male with myelofibrosis who underwent BMT from a HLA-matched unrelated donor. He developed acute pericarditis on day 3. At this time, PCR and Ab testing of his peripheral blood revealed no viral pathogens. His symptoms subsequently improved, with the ST-elevation resolving at day 12 after BMT. However, he experienced septic shock on day 12, and constrictive pericarditis and cardiac tamponade were diagnosed by UCG at this time. Despite the recovery of his sepsis, hypotension persisted because of cardiac tamponade. He achieved neutrophilengraftment on day 32 after BMT. On day 33 after BMT for the treatment of cardiac tamponade, we performed radioscopyguided pericardial centesis and aspirated bloody pericardial effusion. PCR testing and culture testing again failed to detect any bacteria, fungi, acid-fast bacteria or any viral pathogens. However, because of the re-accumulation of the pericardial effusion, we imposed continuous aspiration with a pericardial catheter on day 36. Thereafter, a bloody pericardial effusion was aspirated daily and frequent red cell transfusions were needed. Fortunately, the pericardial effusion decreased after day 90 and the catheter was removed on day 124. On day 115 after BMT, he developed severe GvHD diagnosed by gut and liver biopsies. Despite the treatment with methylprednisolone and low-dose antithymocyte globulin as a second-line therapy, he died from sepsis and multi-organ failure on day 171 after BMT.
To the best of our knowledge, this is the first reported case of constrictive pericarditis following acute pericarditis owing to HSCT, and the first to focus on acute pericarditis before engraftment in HSCT. Serious cardiac complications soon after HSCT are reportedly rare, 1,2 which is consistent with the low incidence of symptomatic acute pericarditis before engraftment in our study (4/464; 0.9%). Subclinical cardiac events are reportedly more frequent after HSCT with MAC regimens, 3 supporting the notion that mild acute pericarditis after HSCT may be more frequent than previously thought.
Regarding early cardiac complications after HSCT, treatmentrelated consequences are well known in conditioning regimens (for example, high-dose Cy). 1, 4 There was no significant difference in the incidence of acute pericarditis between the patients who received MAC and those who received reduced-intensity conditioning regimens (2/352 vs 2/112 patients). Because all cases with acute pericarditis in our study received TBI, the possibility that this may contribute to the disease cannot be excluded. However, the direct association between acute pericarditis and TBI has never been reported.
Regarding cardiac status before HSCT, Murdych et al. 2 indicated the associations between serious cardiac complications and anthracycline exposure or left ventricular function before BMT. Nevertheless, in our cases, pre-transplant examination showed no cardiac abnormalities; moreover, the patient with the most severe case of pericarditis (case 2) did not receive any anthracycline (Table 1) . Thus, cardiac status before HSCT may not be a leading cause of acute pericarditis.
Infectious pericarditis has been reported following HSCT, specifically because of Legionella pneumophila and Mycobacterium tuberculosis. 5, 6 In our study, we did not detect any fungal or bacterial pathogens in blood cultures and failed to identify any viral pathogens by PCR testing in three of the four cases. Although conditioning regimens may be a more important factor than infection in acute pericarditis before engraftment in HSCT, larger studies are needed to clarify this assertion.
Acute pericarditis was a self-limited disease in three of the four cases; nevertheless, case 2 developed severe constrictive pericarditis and pericardial bleeding following acute pericarditis in the context of negative microbiological tests and a conditioning regimen that comprised fludarabine, busulfan and TBI. The role of this combination in the development of this patient's complications cannot be excluded.
Despite the poor outcome with the treatments used for case 2, alternative treatments may not have yielded better outcomes. The use of short-term methotrexate might have led to accumulation in the pericardium during acute pericarditis that may have contributed to the development of constrictive pericarditis. Extensive epicardiectomy is also reported to be curative for effusive-constrictive pericarditis. 7 However, this would have been difficult to perform because of pancytopenia caused by graft failure. Finally, colchicine has also been used for acute pericarditis, and can reportedly reduce the risk of recurrent pericarditis. 8 Although acute pericarditis before engraftment in HSCT may be self-limited, as was the case for most of patients in our report, colchicine could be useful for the prevention of recurrent pericarditis following HSCT and warrants further large-scale investigation such as registry-based study.
The cardiovascular system is a potential target of GvHD. 9, 10 Although, chronic pericarditis with pericardial effusion after HSCT can be associated with chronic GvHD, 11,12 it has not been reported following early acute pericarditis. Although all of our cases received hematopoietic stem cells from unrelated donors, no patient who received HSCT from an HLA-mismatched donor experienced acute pericarditis. This suggested that an immunological reaction like GvHD has a limited role in the disease. In case 2, the late constrictive pericarditis might have been a manifestation of GvHD or some unknown immune reaction. The tissue damage caused by the acute pericarditis shortly after BMT might have induced it.
In conclusion, acute pericarditis before engraftment is a rare complication of HSCT that is generally self-limiting. However, our cases suggest the need for careful observation for the development of chronic pericarditis. 
